BNTX

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Retrieved on: 
Sunday, April 7, 2024
BNTX, Survival, Entrepreneurship, Genentech, Disease, BioNTech, Patient, Neoplasm, Tissue, Messenger, PDAC, Roche, Uridine, Safety, Cancer, De novo, Recurrence, Blood, Vaccine

The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells.

Key Points: 
  • The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells.
  • The persistence of T cels was associated with a longer median recurrence-free survival in cancer vaccine responders.
  • “These new data are an early signal for the potential of our individualized mRNA cancer vaccine approach in this indication with an unmet medical need.
  • Over 80% of the vaccine-induced neoantigen-specific T cells could still be detected up to three years post administration in patients with an immune response.

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Retrieved on: 
Wednesday, March 20, 2024
Novartis, BNTX, Prostate cancer, Supervisory board, Survival, Science, BioNTech, COVID-19, Patient, Lung, Breast, Prostate, Cancer, Translation, Marketing, Development, Pharmaceutical industry

Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.

Key Points: 
  • Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.
  • Annemarie Hanekamp is a seasoned pharmaceutical executive experienced in developing patient-focused commercial strategies for innovative oncology products encompassing sales, marketing and market access.
  • I believe its COVID-19 vaccine will only be the beginning of a series of approved products to follow in the years to come,” said Annemarie Hanekamp, designated Chief Commercial Officer at BioNTech.
  • Annemarie Hanekamp is a Dutch citizen and holds degrees in biomedical sciences as well as organizational leadership.

The Gross Law Firm Notifies BioNTech SE Investors of a Class Action Lawsuit and Upcoming Deadline – BNTX

Retrieved on: 
Tuesday, March 12, 2024
NEXT, BioNTech, Risk, COVID-19, BNTX, Pfizer–BioNTech COVID-19 vaccine, Fraud, Security (finance)

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of BioNTech SE.

Key Points: 
  • NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of BioNTech SE.
  • Shareholders who purchased shares of BNTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE (BNTX)

Retrieved on: 
Monday, March 11, 2024
Class Action Lawsuit, Professional Services, Legal, BNTX, COVID, Forecasting, Law, Pfizer, BioNTech, Risk, COVID-19, Defendant, News, The Company, Suite, Pfizer–BioNTech COVID-19 vaccine, Court, Pharmaceutical industry

The Law Offices of Frank R. Cruz reminds investors of the upcoming March 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX ) securities between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).

Key Points: 
  • The Law Offices of Frank R. Cruz reminds investors of the upcoming March 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX ) securities between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).
  • On this news, BioNTech’s stock price fell $13.81, or 7.5%, to close at $169.30 per share on August 8, 2022, thereby injuring investors.
  • On this news, BioNTech’s stock price fell $4.60, or 3.6%, to close at $123.60 per share on March 27, 2023.
  • Then, on November 16, 2023, BioNTech released its third quarter 2023 financial results, confirming that “[i]nventory write-downs by BioNTech’s collaboration partner Pfizer .

BNTX DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

Retrieved on: 
Sunday, March 10, 2024
Titan, Pfizer–BioNTech COVID-19 vaccine, Court, BioNTech, Class, Plaintiff, Pfizer, Risk, Advertising, COVID-19, BNTX

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

BNTX DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX

Retrieved on: 
Monday, March 11, 2024
Titan, Pfizer–BioNTech COVID-19 vaccine, Court, BioNTech, Class, Pfizer, Risk, Advertising, COVID-19, BNTX

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

BIONTECH SE (NASDAQ: BNTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE

Retrieved on: 
Monday, March 11, 2024
Pfizer–BioNTech COVID-19 vaccine, BioNTech, Pfizer, ADS, Cancer, Court, Biotechnology, News, Advertising, Complaint, District court, Risk, COVID-19, BNTX, Infection, Defendant, Security (finance)

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

FINAL DEADLINE REMINDER FOR BNTX INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against BioNTech SE (BNTX)

Retrieved on: 
Monday, March 11, 2024
Ladewig, Pfizer–BioNTech COVID-19 vaccine, ADS, Court, Person, BioNTech, Omicron, News, Fraud, CFTC, District court, Annual report, Lead, COVID-19, Medicare, IRS, BNTX, COVID, LLP, Cost, COPY, Pharmaceutical industry

The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, March 11, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Cancer, Court, Biotechnology, Person, The Company, BioNTech, Omicron, Food, Complaint, Risk, COVID-19, BNTX, Infection, Pharmaceutical industry

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.

Key Points: 
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • The Company has developed and continues to develop, among other products and product candidates, Comirnaty, a COVID-19 vaccine, in collaboration with Pfizer Inc. (“Pfizer”).
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024

Retrieved on: 
Monday, March 11, 2024
NSCLC, Docetaxel, Messenger, BioNTech, Spacecraft, AACR, Entrepreneurship, ADC, Safety, Roche, Pharmacokinetics, PDAC, BNTX, Abstract, Patient, Clinical trial, Pancreatic cancer, Cancer, Vaccine

MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California, from April 5-10, 2024.

Key Points: 
  • MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California, from April 5-10, 2024.
  • The oral and poster presentations will feature BioNTech’s investigational mRNA-based cancer vaccine and novel investigational antibody-drug conjugate (“ADC”) approaches.
  • BioNTech has established a diversified clinical oncology pipeline of more than 20 clinical programs along mRNA-based therapeutic cancer vaccines, targeted therapies comprising cell therapies and ADCs, and novel immunomodulators in unmet medical need solid tumor indications.
  • These candidates are currently being evaluated in more than 30 clinical studies, including nine programs in advanced Phase 2 trials and two candidates in pivotal Phase 3 trials.